Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Humanin: Evidence Summary
Evidence summary for Humanin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Humanin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Neuroprotection (Alzheimer's) | Tier D | 0 | Animal and cell-culture data only; no human therapeutic trials |
| Metabolic syndrome | Tier D | 0 | Human biomarker correlations only; no interventional studies |
| Anti-aging / cytoprotection | Tier D | 0 | Endogenous levels measured as biomarker; no exogenous administration in humans |
References (5)
- A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ — Hashimoto Y, et al. . Proceedings of the National Academy of Sciences (2001) PMID: 11371646
- Humanin: a novel central regulator of peripheral insulin action — Muzumdar RH, et al. . PLoS ONE (2009) PMID: 19623253
- Mitochondrial-derived peptides in aging and age-related diseases — Kim SJ, et al. . GeroScience (2017) PMID: 32910336
- Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress — Bachar AR, et al. . Cardiovascular Research (2010) PMID: 20562421
- Humanin peptide suppresses apoptosis by interfering with Bax activation — Guo B, et al. . Nature (2003) PMID: 12732850